Cancer pill may keep blood disease at bay after transplant
NCT ID NCT05127174
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy after a stem cell transplant in people with myeloproliferative neoplasms, a group of blood cancers. The goal was to see if taking the pill daily could prevent the cancer from coming back. Only 12 people were enrolled, and the study was terminated early, so it is unclear if the approach works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fedratinib (Inrebic), a pill taken daily that targets cancer-related enzymes
What this could lead to
If successful, this could point toward a way to keep blood cancers from returning after a stem cell transplant.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The drug may cause side effects like liver problems or worsen graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.